{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T19:08:10Z","timestamp":1792609690070,"version":"4.5.0"},"reference-count":37,"publisher":"Georg Thieme Verlag KG","issue":"01","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Thromb Hemost"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Non-factor replacement therapies (NFTs) have been developed to address the limitations of conventional replacement therapies, aiming to improve hemostasis and provide enhanced protection against bleeding episodes and long-term joint damage for patients both with and without inhibitors. Factor VIII (FVIII)-mimetic agents, such as emicizumab, have transformed the management of hemophilia A with inhibitors, offering a lower treatment burden and an effective alternative for those without inhibitors as well. Rebalancing agents, including anti-tissular factor pathway inhibitor agents (concizumab and marstacimab) and serpin inhibitors like fitusiran, have shown promising efficacy for patients with hemophilia B with inhibitors and other hemophilia subtypes. Administered subcutaneously, NFTs generate stable thrombin levels and feature a long half-life, which can shift severe hemophilia toward a milder phenotype. These therapies are effective regardless of inhibitor status and hold potential for application in other bleeding disorders. Evaluating the potential thrombotic risk after implementing mitigation measures, along with the development of anti-drug antibodies (ADAs), remain critical areas for further analysis. NFTs pose additional challenges due to their complex mechanism of action and the absence of a standardized laboratory assessment method. Unresolved issues include optimal management strategies for major surgeries and tailored approaches for safe use in older populations. This review highlights the progress and future potential of NFTs in treating persons with hemophilia.<\/jats:p>","DOI":"10.1055\/s-0044-1796651","type":"journal-article","created":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T19:23:54Z","timestamp":1732908234000},"page":"023-027","source":"Crossref","is-referenced-by-count":21,"title":["Non-factor Therapies for Hemophilia: Achievements and Perspectives"],"prefix":"10.1055","volume":"51","author":[{"given":"Victor","family":"Jim\u00e9nez-Yuste","sequence":"additional","affiliation":[{"name":"Department of Haematology, Hospital Universitario La Paz-IdiPaz, Aut\u00f3noma University, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2024,11,29]]},"reference":[{"issue":"06","key":"ref1","doi-asserted-by":"crossref","first-page":"e911","DOI":"10.1097\/HS9.0000000000000911","article-title":"Nonfactor therapies for hemophilia","volume":"7","author":"G Young","year":"2023","journal-title":"HemaSphere"},{"issue":"S 03","key":"ref2","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/hae.14976","article-title":"Benefits and risks of non-factor therapies: redefining haemophilia treatment goals in the era of new technologies","volume":"30","author":"M E Mancuso","year":"2024","journal-title":"Haemophilia"},{"issue":"02","key":"ref3","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/ejh.13193","article-title":"Inhibitors in haemophilia A and B: Management of bleeds, inhibitor eradication and strategies for difficult-to-treat patients","volume":"102","author":"R Ljung","year":"2019","journal-title":"Eur J Haematol"},{"issue":"10","key":"ref4","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/nm.2942","article-title":"A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model","volume":"18","author":"T Kitazawa","year":"2012","journal-title":"Nat Med"},{"issue":"01","key":"ref5","doi-asserted-by":"crossref","first-page":"2149053","DOI":"10.1080\/19420862.2022.2149053","article-title":"Kinetic analysis of ternary and binary binding modes of the bispecific antibody emicizumab","volume":"15","author":"S Mak","year":"2023","journal-title":"MAbs"},{"issue":"09","key":"ref6","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"377","author":"J Oldenburg","year":"2017","journal-title":"N Engl J Med"},{"issue":"24","key":"ref7","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1182\/blood.2019001869","article-title":"A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors","volume":"134","author":"G Young","year":"2019","journal-title":"Blood"},{"issue":"09","key":"ref8","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1056\/NEJMoa1803550","article-title":"Emicizumab prophylaxis in patients who have hemophilia A without inhibitors","volume":"379","author":"J Mahlangu","year":"2018","journal-title":"N Engl J Med"},{"issue":"06","key":"ref9","doi-asserted-by":"crossref","first-page":"e295","DOI":"10.1016\/S2352-3026(19)30054-7","article-title":"Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study","volume":"6","author":"S W Pipe","year":"2019","journal-title":"Lancet Haematol"},{"issue":"14","key":"ref10","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1182\/blood.2023021832","article-title":"Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial","volume":"143","author":"S W Pipe","year":"2024","journal-title":"Blood"},{"issue":"02","key":"ref11","doi-asserted-by":"crossref","first-page":"e12670","DOI":"10.1002\/rth2.12670","article-title":"Prophylactic emicizumab for hemophilia A in the Asia-Pacific region: a randomized study (HAVEN 5)","volume":"6","author":"R Yang","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"issue":"03","key":"ref12","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1016\/S2352-3026(22)00377-5","article-title":"Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 study","volume":"10","author":"C N\u00e9grier","year":"2023","journal-title":"Lancet Haematol"},{"issue":"16","key":"ref13","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1182\/blood.2020009217","article-title":"Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies","volume":"137","author":"M U Callaghan","year":"2021","journal-title":"Blood"},{"issue":"04","key":"ref14","doi-asserted-by":"crossref","first-page":"102415","DOI":"10.1016\/j.rpth.2024.102415","article-title":"Emicizumab is well tolerated and effective in people with congenital hemophilia A regardless of age, severity of disease, or inhibitor status: a scoping review","volume":"8","author":"G Young","year":"2024","journal-title":"Res Pract Thromb Haemost"},{"issue":"06","key":"ref15","doi-asserted-by":"crossref","first-page":"102181","DOI":"10.1016\/j.rpth.2023.102181","article-title":"Mim8, a novel factor VIIIa mimetic bispecific antibody, shows favorable safety and pharmacokinetics in healthy adults","volume":"7","author":"P Persson","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"issue":"S 01","key":"ref16","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1182\/blood-2020-137006","article-title":"A novel next-generation FVIII Mimetic, Mim8, has a favourable safety profile. Results from a 26-week safety study in cynomolgus monkeys","volume":"136","author":"B Lauritzen","year":"2020","journal-title":"Blood"},{"issue":"02","key":"ref18","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.jtha.2023.09.034","article-title":"A bispecific antibody NXT007 exerts a hemostatic activity in hemophilia A monkeys enough to keep a nonhemophilic state","volume":"22","author":"Y Teranishi-Ikawa","year":"2024","journal-title":"J Thromb Haemost"},{"issue":"19","key":"ref19","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1182\/blood-2013-11-512764","article-title":"Biology of tissue factor pathway inhibitor","volume":"123","author":"J P Wood","year":"2014","journal-title":"Blood"},{"issue":"09","key":"ref20","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJMoa2216455","article-title":"Phase 3 trial of concizumab in hemophilia with inhibitors","volume":"389","author":"T Matsushita","year":"2023","journal-title":"N Engl J Med"},{"issue":"02","key":"ref21","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/bjh.18420","article-title":"A phase 1b\/2 clinical study of marstacimab, targeting human tissue factor pathway inhibitor, in haemophilia","volume":"200","author":"J N Mahlangu","year":"2023","journal-title":"Br J Haematol"},{"issue":"02","key":"ref22","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/bjh.18495","article-title":"Long-term safety and efficacy of the anti-tissue factor pathway inhibitor marstacimab in participants with severe haemophilia: Phase II study results","volume":"200","author":"J Mahlangu","year":"2023","journal-title":"Br J Haematol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1182\/blood.2023021864","article-title":"Fitusiran prophylaxis in people with hemophilia A or B who switched from prior BPA\/CFC prophylaxis (ATLAS-PPX)","volume":"143","author":"G Kenet","year":"2024","journal-title":"Blood J"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0140-6736(23)00284-2","article-title":"Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial","volume":"401","author":"G Young","year":"2023","journal-title":"Lancet"},{"issue":"05","key":"ref26","doi-asserted-by":"crossref","first-page":"e322","DOI":"10.1016\/S2352-3026(23)00037-6","article-title":"Fitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors (ATLAS-A\/B): a multicentre, open-label, randomised, phase 3 trial","volume":"10","author":"A Srivastava","year":"2023","journal-title":"Lancet Haematol"},{"issue":"S 01","key":"ref28","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1182\/blood-2022-170245","article-title":"Pre-clinical characterization of VGA039, an anti-protein S monoclonal antibody being developed as a universal hemostatic agent for various bleeding disorders","volume":"140","author":"L Leong","year":"2022","journal-title":"Blood"},{"issue":"06","key":"ref29","doi-asserted-by":"crossref","first-page":"e772","DOI":"10.1111\/hae.14421","article-title":"Patient preference for emicizumab versus prior factor therapy in people with haemophilia A: results from the HAVEN 3 and HAVEN 4 studies","volume":"27","author":"A Parnes","year":"2021","journal-title":"Haemophilia"},{"issue":"05","key":"ref30","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/hae.14363","article-title":"The effect of emicizumab prophylaxis on long-term, self-reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies","volume":"27","author":"M W Skinner","year":"2021","journal-title":"Haemophilia"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.2147\/PPA.S470091","article-title":"The concizumab pen-injector is easy to use and preferred by hemophilia patients and caregivers: a usability study assessing pen-injector handling and preference","volume":"18","author":"N Kahr Rasmussen","year":"2024","journal-title":"Patient Prefer Adherence"},{"issue":"04","key":"ref32","doi-asserted-by":"crossref","first-page":"102476","DOI":"10.1016\/j.rpth.2024.102476","article-title":"Concizumab prophylaxis in persons with hemophilia A or B with inhibitors: patient-reported outcome results from the phase 3 explorer7 study","volume":"8","author":"H Tran","year":"2024","journal-title":"Res Pract Thromb Haemost"},{"issue":"06","key":"ref33","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1182\/blood.2019004334","article-title":"A hemophilia A mouse model for the in vivo assessment of emicizumab function","volume":"136","author":"S Ferri\u00e8re","year":"2020","journal-title":"Blood"},{"issue":"05","key":"ref35","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/hae.13820","article-title":"Marstacimab, a tissue factor pathway inhibitor neutralizing antibody, improves coagulation parameters of ex vivo dosed haemophilic blood and plasmas","volume":"25","author":"S Patel-Hett","year":"2019","journal-title":"Haemophilia"},{"issue":"10","key":"ref36","first-page":"e30212","article-title":"The implication of new developments in hemophilia treatment on its laboratory evaluation","volume":"14","author":"G Anandani","year":"2022","journal-title":"Cureus"},{"issue":"05","key":"ref37","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/nm.3847","article-title":"An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia","volume":"21","author":"A Sehgal","year":"2015","journal-title":"Nat Med"},{"issue":"01","key":"ref38","doi-asserted-by":"crossref","first-page":"102306","DOI":"10.1016\/j.rpth.2023.102306","article-title":"Pharmacokinetics and coagulation biomarkers in children and adults with hemophilia A receiving emicizumab prophylaxis every 1, 2, or 4 weeks","volume":"8","author":"A Kiialainen","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"issue":"06","key":"ref39","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1111\/jth.15270","article-title":"Targeting of antithrombin in hemophilia A or B with investigational siRNA therapeutic fitusiran-Results of the phase 1 inhibitor cohort","volume":"19","author":"K J Pasi","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"09","key":"ref40","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1016\/j.jtha.2024.05.033","article-title":"Targeting tissue factor pathway inhibitor with concizumab to improve hemostasis in patients with Glanzmann thrombasthenia: an in vitro study","volume":"22","author":"J Dubut","year":"2024","journal-title":"J Thromb Haemost"},{"issue":"03","key":"ref41","doi-asserted-by":"crossref","first-page":"102405","DOI":"10.1016\/j.rpth.2024.102405","article-title":"Emicizumab is efficacious in people with hemophilia A with comorbidities aged \u226550 years: analysis of 4 phase III trials","volume":"8","author":"V Jim\u00e9nez-Yuste","year":"2024","journal-title":"Res Pract Thromb Haemost"}],"container-title":["Seminars in Thrombosis and Hemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0044-1796651.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T18:36:57Z","timestamp":1737484617000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0044-1796651"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,29]]},"references-count":37,"journal-issue":{"issue":"01","published-online":{"date-parts":[[2025,1,21]]},"published-print":{"date-parts":[[2025,2]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0044-1796651","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0094-6176","1098-9064"],"issn-type":[{"value":"0094-6176","type":"print"},{"value":"1098-9064","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,29]]}}}